GW is the global leader in developing cannabinoid-based medicines. Cannabidiol (approved by FDA as Epidiolex^® in the United States) is in development to treat certain rare and catastrophic forms of childhood-onset epilepsy that currently have few treatment options.

Healthcare Professionals: Learn more about cannabidiol (CBD) development

Clinicians & Researchers

Investors & Media

GW’s vision is to be the global leader in prescription cannabinoid medicines, developing and commercializing pharmaceutical products which address clear unmet needs.
Justin Gover, Chief Executive Officer

RECENT NEWS

Nov 06, 2018

GW Pharmaceuticals to Report Fourth Quarter and Year-End Financial Results and Host Conference Call on 27 November, 2018

LONDON , Nov. 06, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 27 November, 2018 its

Nov 01, 2018

EPIDIOLEX® (cannabidiol) Oral Solution – the First FDA-approved Plant-derived Cannabinoid Medicine – Now Available by Prescription in the U.S.

- Medication indicated for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome, two rare, severe childhood-onset epilepsies - - Comprehensive support program available for eligible patients - LONDON and CARLSBAD, Calif., Nov.

Oct 05, 2018

GW Pharmaceuticals plc Announces the Closing of Public Offering of ADSs, Raising Gross Proceeds of $345 Million and Full Exercise of Underwriters' Option to Purchase Additional ADSs

LONDON and CARLSBAD, Calif. , Oct. 05, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH, "GW," and the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today

Home

RECENT NEWS